Studying Biomarkers in Samples From Younger Patients With Kidney Cancer

Children's Oncology Group

Status: Withdrawn

Conditions: Childhood Kidney Neoplasm; Rhabdoid Tumor of the Kidney; Congenital Mesoblastic Nephroma; Clear Cell Renal Cell Carcinoma

Treatments: Other: Laboratory Biomarker Analysis

Study type: Observational

Funder types: NETWORK; NIH

Identifiers

NCT01642095

COG-AREN12B8

AREN12B8

CDR0000736805

NCI-2012-01987 (Registry Identifier)

Details and patient eligibility

About

This laboratory study is looking into biomarkers in samples from younger patients with kidney cancer. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer.

Full description

PRIMARY OBJECTIVES:

I. To determine whether focal adhesion kinase (FAK) is expressed and if FAK is phosphorylated in pediatric renal tumors.

OUTLINE:

Archived tumor tissue samples are analyzed for FAK expression by immunohistochemistry (IHC). IHC staining is compared in normal renal tissue, Wilms tumor (routine and anaplastic), malignant rhabdoid tumor of the kidney, clear cell sarcoma of the kidney, and mesoblastic nephroma.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Formalin-fixed, paraffin-embedded tissue samples from patients diagnosed with the following renal tumors:

  • Anaplastic Wilms tumor
  • Malignant rhabdoid tumor of the kidney
  • Clear cell sarcoma of the kidney
  • Mesoblastic nephroma

Trial design

0 participants in 1 patient group

Basic science (FAK expression)

Description:

Archived tumor tissue samples are analyzed for FAK expression by IHC. IHC staining is compared in normal renal tissue, Wilms tumor (routine and anaplastic), malignant rhabdoid tumor of the kidney, clear cell sarcoma of the kidney, and mesoblastic nephroma.

Treatment:

Other: Laboratory Biomarker Analysis